ACHN News and Press, Achison Inc Cl A From 05/02/19

After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor ; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas. ...

ACHN stock is one of the top performing biotech stocks so far in 2019. Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) are up over 115% since early January amid several key clinical updates. In Wednesday’s session, Achillion Pharmaceuticals’ stock moved up by 4.78%, to c...

Achillion Pharmaceuticals (NASDAQ: ACHN ) has enrolled 23 patients in Phase 2 ACH-4471 six and 12-month clinical trials for patients with C3 glomerulopathy (C3G), a disease affecting the kidney for which there is no approved therapy. More news on: Achillion Pharmaceuticals, Inc., Healthc...

- Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials - - Targeting end-of-Phase 2 meeting with FDA in fourth quarter of 2019 - BLUE BELL, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutic...

- Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab - - Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE BELL, Pa., March 27, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasd...

I’ve been following Achillion Pharmaceuticals ( ACHN ) for quite some time, but became more interested after the company reported positive results of its factor D inhibitor ACH-4471 in two rare diseases – PNH and C3G. The problem with PNH is that the results aren’t goo...

The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more ...

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q4 GAAP EPS of -$0.12  beats by $0.03. More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 - - Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting - - Next-generation factor D inhibitor ACH-5228 US IND anticipated in Q4:2019 - - Reduced 2018 net cash spend to $60 million, pro...

The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more ...